Association between IL-17A rs2275913 gene polymorphism and the levels of inflammatory markers (NFKB1 and IL-17A) in Iraqi patients with diabetic nephropathy (T2DNP)

H. A. Alhour; R. A. Abdulkareem; H. H. K. Al-Shukri

doi:10.15421/0225051

H. A. Alhour University of Baghdad
R. A. Abdulkareem University of Baghdad
H. H. K. Al-Shukri Al-Qasim Green University

Keywords: NFKB1, IL-17A, diabetic nephropathy, rs2275913, SNP.

Abstract

One of the most common complications of chronic kidney disease (CKD) is diabetic nephropathy (T2DNP), which is i n creasing worldwide. This study aimed to examine the association between IL-17A rs2275913 gene polymorphism and diabetic nephropathy (T2DNP) in Iraqi patients. This study included 150 participants divided into three groups: Control, T2DM ( T ype 2 diabetes mellitus) , and T2DNP. Inflammatory markers (IL-17A) were investigated following the protocol provide d with the ELISA kit. B riefly, the enzyme immunoassay s known as human NFKB1 and IL-17A were used to quantitatively and specif i cally identify these cytokines in human serum in vitro . The polymerase chain reaction method known as restriction fragment length polymorphism (PCR-RFLP) was used to detect the IL-17A rs2275913 SNP with specific utiliz ation of particular primer sequences. The study found that levels of NFKB1 and IL-17A were significantly higher in the diabetic groups (T2DM and T2DNP) compared to the C ontrol group. The C ontrol group had NFKB1 levels of 1.15 ± 0.28, while the T2DM and T2DNP groups had levels of 4.83 ± 1.49 and 8.56 ± 1.16, respectively. For IL-17A, the C ontrol group showed levels of 19.67 ± 1.85, while T2DM and T2DNP had levels of 43.04 ± 10.32 and 131.81 ± 13.13. The T2DN group exhibited the highest levels for both parameters, with a statistically significant p-value of 0.001 and the multinomial regression analysis examined the associ a tion between IL-17A gene polymorphism and T2DM/T2DNP. For the comparison of T2DM versus Control, the AA genotype had an odds ratio (OR) of 5.357, and the AG genotype had an OR of 2.857, both with significant p-values. In the T2DN versus Control comparison, the AA genotype had an OR of 6.562, and the AG genotype had an OR of 3.542, also significant. Ho w ever, no significant associations were found between IL-17A genotypes and T2DNP compared to T2DM. The study concludes that there is a significant correlation between IL-17A gene polymorphism and diabetic nephropathy (T2DNP) in Iraqi patients, that both T2DM and T2DNP groups had higher levels of the inflammatory markers NFKB1 and IL-17A than the C ontrol group, with the T2DNP group having the highest levels, and that certain IL-17A genotypes are associated with increased odds of developing T2DM and T2DN, but that there were no significant differences between T2DNP and T2DM in terms of IL-17A genotypes. These findings highlight the significance of IL-17A as a potential biomarker and genetic factor in the progression of diabetic nephropathy, suggesting directions for future research and clinical implications in managing diabetic nephropathy as a CKD complication.

References

Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013). Kidney disease and increased mortality risk in type 2 diabetes. Journal of the American Society of Nephrology, 24(2), 302–308.

Al-Gazally, M. E., Al-Awad, A. S., & Kzar, H. H. (2016). Assessment of antioxidant status in different genotypes/phenotypes at codon 72 of TP53 gene for patients with sporadic colorectal cancer in Babylon province. International Journal of PharmTech Research, 9(3), 280–286.

Al-Gazally, M. E., Al-Awad, A. S., & Kzar, H. H. (2016). Evaluating the superoxide dismutase-1 status in wild type and mutant at codons 12 and 13 of KRAS gene spectrum for the patients with sporadic colorectal cancer International Journal of PharmTech Research, 9(3), 272–279.

Donath, M. Y., & Shoelson, S. E. (2011). Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology, 11(2), 98–107.

Galvan, D. L., & Danesh, F. R. (2016). Paradoxical role of IL-17 in progression of diabetic nephropathy. Journal of the American Society of Nephrology, 27(3), 657–658.

Gui, H., Chen, X., Ye, L., & Ma, H. (2023). Seven basement membrane-specific expressed genes are considered potential biomarkers for the diagnosis and treatment of diabetic nephropathy. Acta Diabetologica, 60(4), 493–505.

Hammad, A., Mosaad, Y. M., Hammad, E. M., Elhanbly, S., El-Bassiony, S. R., Al-Harrass, M. F., Eid, R., Sharaf Eldein, O. A., Alsawah, G. A., Yahia, S., & Fawzy, I. M. (2015). Interleukin-17Ars2275913, interleukin-17Frs763780 and rs2397084 gene polymorphisms as possible risk factors in juvenile lupus and lupus related nephritis. Autoimmunity, 49(1), 31–40.

Lavoz, C., Matus, Y. S., Orejudo, M., Carpio, J. D., Droguett, A., Egido, J., Mezzano, S., & Ruiz-Ortega, M. (2019). Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy. Kidney International, 95(6), 1418–1432.

Lavoz, C., Rayego-Mateos, S., Orejudo, M., Opazo-Ríos, L., Marchant, V., Marquez-Exposito, L., Tejera-Muñoz, A., Navarro-González, J. F., Droguett, A., Ortiz, A., Egido, J., Mezzano, S., Rodrigues-Diez, R. R., & Ruiz-Ortega, M. (2020). Could IL-17A be a novel therapeutic target in diabetic nephropathy? Journal of Clinical Medicine, 9(1), 272.

Li, J., Wei, J., Xu, P., Yan, M., Li, J., Chen, Z., & Jin, T. (2016). Impact of diabetes-related gene polymorphisms on the clinical characteristics of type 2 diabetes Chinese Han population. Oncotarget, 7(51), 85464–85471.

Li, X., Lu, L., Hou, W., Huang, T., Chen, X., Qi, J., Zhao, Y., & Zhu, M. (2021). Epigenetics in the pathogenesis of diabetic nephropathy. Acta Biochimica et Biophysica Sinica, 54(2), 163–172.

Lontchi-Yimagou, E., Sobngwi, E., Matsha, T. E., & Kengne, A. P. (2013). Diabetes mellitus and inflammation. Current Diabetes Reports, 13(3), 435–444.

Ma, J., Li, Y. J., Chen, X., Kwan, T., Chadban, S. J., & Wu, H. (2019). Interleukin 17A promotes diabetic kidney injury. Scientific Reports, 9(1), 2264.

Margaryan, S., Kriegova, E., Fillerova, R., Smotkova Kraiczova, V., & Manukyan, G. (2020). Hypomethylation of IL1RN and NFKB1 genes is linked to the dysbalance in IL1β/IL-1Ra axis in female patients with type 2 diabetes mellitus. PLoS One, 15(5), e0233737.

Młynarska, E., Buławska, D., Czarnik, W., Hajdys, J., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2024). Novel insights into diabetic kidney disease. International Journal of Molecular Sciences, 25(18), 10222.

Navarro-González, J. F., & Mora-Fernández, C. (2008). The role of inflammatory cytokines in diabetic nephropathy. Journal of the American Society of Nephrology, 19(3), 433–442.

Navarro-González, J. F., Jarque, A., Muros, M., Mora, C., & García, J. (2009). Tumor necrosis factor-α as a therapeutic target for diabetic nephropathy. Cytokine and Growth Factor Reviews, 20(2), 165–173.

Navarro-González, J. F., Mora-Fernández, C., de Fuentes, M. M., & García-Pérez, J. (2011). Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nature Reviews Nephrology, 7(6), 327–340.

Nazarian, A., Hejazian, S. M., Ahmadian, E., Zununi Vahed, S., Haghi, M., Mobasseri, M., & Ardalan, M. (2022). IL-17A rs2275913 gene polymorphism in patients with diabetic nephropathy. Immunopathologia Persa, 2022, e29320.

Nowak, N. (2020). Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: From current human evidence to future possibilities. Journal of Diabetes Investigation, 11(5), 1085–1096.

Qiu, A.-W., Cao, X., Zhang, W.-W., & Liu, Q.-H. (2020). IL-17A is involved in diabetic inflammatory pathogenesis by its receptor IL-17RA. Experimental Biology and Medicine, 246(1), 57–65.

Qu, Z., Wang, B., Jin, Y., Xiao, Q., Zhao, Y., Zhao, D., & Yang, L. (2023). Shenkang protects renal function in diabetic rats by preserving nephrin expression. BMC Complementary Medicine and Therapies, 23(1), 244.

Rajaei, E., Jalali, M. T., Shahrabi, S., Asnafi, A. A., & Pezeshki, S. M. S. (2019). HLAs in autoimmune diseases: Dependable diagnostic biomarkers? Current Rheumatology Reviews, 15(4), 269–276.

Russo, G., Piscitelli, P., Giandalia, A., Viazzi, F., Pontremoli, R., Fioretto, P., & De Cosmo, S. (2020). Atherogenic dyslipidemia and diabetic nephropathy. Journal of Nephrology, 33(5), 1001–1008.

Salama-Frisbie, R., Molina-Flores, C. A., Urraza-Robledo, A. I., Gutiérrez-Pérez, M. E., Miranda-Pérez, A. A., Gutiérrez-Salas, A. A., Haro-Santa Cruz, J., & López-Márquez, F. C. (2024). Association of polymorphisms of the IL-17A and IL-17F genes with increased risk of hypertension and obesity in mexican patients with COVID-19. Journal of Interferon and Cytokine Research, 44(2), 60–67.

Sandireddy, R., Yerra, V. G., Areti, A., Komirishetty, P., & Kumar, A. (2014). Neuroinflammation and oxidative stress in diabetic neuropathy: Futuristic strategies based on these targets. International Journal of Endocrinology, 2014, 674987.

Sapra, A., & Bhandari, P. (2023). Diabetes. StatPearls, Treasure Island.

Sasi Kumar, P. K., Sheeja Varghese, S., Kumaran, T., Jaga Desaan, N., Lambo Daran, G. (2021). Association of IL-17A polymorphism with chronic periodontitis in type 1 diabetic patients. Journal of Dentistry, 22(3), 180–186.

Shim, K., Gulhar, R., & Jialal, I. (2019). Exploratory metabolomics of nascent metabolic syndrome. Journal of Diabetes and Its Complications, 33(3), 212–216.

Sønder, S. U., Saret, S., Tang, W., Sturdevant, D. E., Porcella, S. F., & Siebenlist, U. (2011). IL-17-induced NF-κB activation via CIKS/Act1. Journal of Biological Chemistry, 286(15), 12881–12890.

Umanath, K., & Lewis, J. B. (2018). Update on diabetic nephropathy: Core curriculum 2018. American Journal of Kidney Diseases, 71(6), 884–895.

Zhang, X.-X., Kong, J., & Yun, K. (2020). Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: A meta-analysis of observational studies. Journal of Diabetes Research, 2020, 2315607.